Editorial: Membrane domains as new drug targets by Annemiek B. van Spriel et al.
EDITORIAL
published: 02 June 2015
doi: 10.3389/fphys.2015.00172
Frontiers in Physiology | www.frontiersin.org 1 June 2015 | Volume 6 | Article 172
Edited by:
Mario L. Diaz,
Universidad de La Laguna, Spain
Reviewed by:
Raquel Marin,
Universidad de La Laguna, Spain
*Correspondence:
Alessandra Cambi,
alessandra.cambi@radboudumc.nl
Specialty section:
This article was submitted to
Membrane Physiology and Membrane
Biophysics,
a section of the journal
Frontiers in Physiology
Received: 29 April 2015
Accepted: 20 May 2015
Published: 02 June 2015
Citation:
van Spriel AB, van den Bogaart G and
Cambi A (2015) Editorial: Membrane
domains as new drug targets.
Front. Physiol. 6:172.
doi: 10.3389/fphys.2015.00172
Editorial: Membrane domains as new
drug targets
Annemiek B. van Spriel, Geert van den Bogaart and Alessandra Cambi *
Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center,
Nijmegen, Netherlands
Keywords: plasma membrane, microdomains, membrane lipids, lipid rafts, tetraspanin enriched microdomain,
membrane receptors
Our understanding of the plasma membrane of eukaryotic cells has profoundly changed over the
past 40 years (Kusumi et al., 2012). It is now well-understood that at the plasma membrane lipids
and proteins are not randomly distributed, but are highly organized in discrete membrane domains
with specific compositions such as lipid rafts, tetraspanin-enriched microdomains, caveolae or
cortical actin-dependent membrane compartments (Cambi and Lidke, 2012; Kusumi et al., 2012).
Membrane domains act as dedicated platforms for a whole range of cellular functions, such as
cell proliferation, adhesion, migration, and intracellular trafficking, thus being appealing targets
for drug treatment. This possibility has sprouted in numerous research efforts to identify and
characterize drugs that selectively target membrane domains. Drugs may block or promote cellular
functions by inducing, stabilizing, or disrupting the integrity or structure of these membrane
domains.
This Review Topic provides a timely overview of the latest insights in the pharmaceutical
potential of membrane domains, both protein- and lipid-based. Beckmann and colleagues highlight
current research studies and clinical trials revolving around the inhibition of ceramide domain
formation by antidepressants targeting the enzyme acid sphingomyelinase (ASM) (Beckmann et al.,
2014). Considering the involvement of ASM-depending ceramide domains in several diseases
including cancer (Petersen et al., 2013), infectious diseases (Grassme et al., 2003) and major
depression (Gulbins et al., 2013), the impact of drugs that inhibit ASM activity is potentially broad
(Kornhuber et al., 2010).
Milovanovic and Jahn review the roles of microdomains in neurobiology focusing on the
molecular mechanismsmediating domain organization at the presynaptic membrane (Milovanovic
and Jahn, 2015). The organization of SNARE proteins in membrane domains for localized vesicle
docking, release and retrieval is a highly studied topic. SNARE proteins catalyze the final fusion
steps of the neurotransmitter containing synaptic vesicles with the plasma membrane (Jahn and
Scheller, 2006; Hong and Lev, 2014) and are the main targets of the Clostridial neurotoxins, which
are widely used in the clinic as muscle relaxants (Rossetto et al., 2014). The authors not only
provide an overview of the mechanisms that contribute to the clustering of SNARE proteins (van
den Bogaart et al., 2013), but also integrate these into a single and elegant model describing the
organization of SNAREs in membrane domains at the presynaptic membrane.
Navarro and co-workers discuss the therapeutic potential of targeting caveolae (Shvets et al.,
2014) for treatment of cardiovasculature diseases, including atherosclerosis and pulmonary
arterial hypertension (Navarro et al., 2014). Caveolae function in transcytosis of cholesterol-rich
lipoproteins across endothelium of blood vessels and in the regulation of the activities of various
ion channels and G-protein coupled receptors. Navarro and colleagues also review the connection
between caveolae and Parkinson and Alzheimer diseases, where caveola are affected, and discuss
how this may relate to the etiology and pathophysiology of these neurodegenerative diseases.
The authors discuss potential strategies for developing drugs that selectively target caveolae.
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Tetraspanins belong to the superfamily of four-
transmembrane proteins that interact in ciswith othermembrane
proteins and intracellular proteins forming so-called “tetraspanin
microdomains” (Tarrant et al., 2003). These have attracted much
attention as potential drug targets since recent studies have
demonstrated that tetraspanins not only organize proteins in
the plasma membrane, but also that they can directly regulate
signaling pathways (Levy and Shoham, 2005; Lapalombella
et al., 2012; van Spriel et al., 2012). Tetraspanin expression by
tumor cells has been related to tumor progression and metastasis
(Wright et al., 2004; Zoller, 2009; Hemler, 2014).
Ailane et al. describe the potency of targeting the tetraspanin
Co-029/Tspan8 on colorectal tumor cells (Ailane et al., 2014).
The expression profile of Tspan8 is largely restricted to squamous
epithelial cells in the digestive tract, capillary endothelial
cells, nerves, and muscle cells. Tspan8 over-expression has
been documented in different carcinomas which relates to
an increased metastatic capacity of tumor cells and poor
prognosis (reviewed in Zoller, 2009). Here, the effect of a
Tspan8 antibody on colorectal cancer cells was investigated
in tumor cell lines and in a xenogeneic mouse model.
Although no effect on tumor cell proliferation or apoptosis
induction was found in vitro, antibody treatment of tumor-
bearing mice resulted in significantly delayed tumor growth.
Binding of the Tspan8 antibody to the tumor cells may
modify their response to the tumor microenvironment possibly
by disrupting the assembly of tetraspanin microdomains
containing integrins, growth factor receptors, and/or signaling
molecules.
The effectiveness of tetraspanin targeting in hematological
malignancies is concisely reviewed by the group of Muthusamy
(Beckwith et al., 2015). CD37 is highly expressed by B cells,
B cell lymphomas and some leukemias. The historical view
of tetraspanins as membrane organizers or scaffolds may be
incomplete as it has recently been shown that CD37 has direct
signaling capacities (Lapalombella et al., 2012). The intracellular
tails of CD37 contain ITAM-like and ITIM-like motifs that may
recruit PI3K and SHP-1. Coupling of CD37 to the Akt survival
pathway has been shown in CD37-deficient mice that have
defects in humoral immunity (van Spriel et al., 2012). Excitingly,
several CD37-targeting therapeutics have been developed which
are currently under evaluation in clinical trials in patients with B
cell malignancies (Zhao et al., 2007; Heider et al., 2011; Deckert
et al., 2013).
The use of transmembrane proteins as target for intracellular
drug delivery is an exciting possibility discussed by Popov-
Cˇeleketic´ and Van Bergen en Henegouwen, who elaborate on
the role of cancer-specific growth factor receptor domains in
receptor-mediated endocytosis (Popov-Celeketic and van Bergen
EnHenegouwen, 2014). Focusing on the epidermal growth factor
receptor, the authors discuss how membrane receptor clustering
and internalization can be exploited to target cancer cells
using classical antibodies (Okines et al., 2011) and nanobodies
(Heukers et al., 2014) conjugated to cytotoxic pharmaceutical
agents.
Together, we believe our Review Topic provides an exciting
overview of the various targeting and effector strategies of
drugs that selectively target membrane domains. This synergistic
overview brings together previously detached research fields and
disciplines. Given the increasing appreciation of the fundamental
importance of membrane domains in cellular function, we hope
that this overview will foster the development or optimization of
new pharmaceutical strategies for a wide range of human diseases
and disorders.
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